Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $106.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective lifted by HC Wainwright from $88.00 to $106.00 in a report issued on Wednesday morning, MarketBeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q4 2026 earnings at ($0.55) EPS, FY2026 earnings at ($15.85) EPS, FY2027 earnings at $1.37 EPS, FY2028 earnings at $3.65 EPS, FY2029 earnings at $5.97 EPS and FY2030 earnings at $8.49 EPS.

Several other equities analysts have also commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, October 15th. Jefferies Financial Group lifted their price objective on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. The Goldman Sachs Group initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $116.00 price objective on the stock. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Mizuho decreased their target price on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $104.57.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS traded up $1.08 during midday trading on Wednesday, reaching $68.60. 1,088,955 shares of the company traded hands, compared to its average volume of 895,567. Tarsus Pharmaceuticals has a twelve month low of $53.89 and a twelve month high of $91.53. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of -4.52 and a beta of 0.34. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The company has a fifty day moving average price of $74.99 and a 200 day moving average price of $67.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($14.40) EPS for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). The company had revenue of $194.57 million for the quarter, compared to the consensus estimate of $187.83 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. On average, analysts expect that Tarsus Pharmaceuticals will post -12.10 EPS for the current fiscal year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Elizabeth Lin sold 3,180 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $87.50, for a total value of $278,250.00. Following the completion of the transaction, the insider owned 1,590 shares of the company’s stock, valued at approximately $139,125. This represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $90.56, for a total value of $905,600.00. Following the transaction, the chief executive officer directly owned 827,991 shares in the company, valued at $74,982,864.96. This trade represents a 1.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 48,031 shares of company stock valued at $4,004,227 in the last quarter. Corporate insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Eurizon Capital SGR S.p.A. bought a new position in Tarsus Pharmaceuticals in the 3rd quarter valued at about $35,000. Parallel Advisors LLC raised its position in shares of Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after buying an additional 291 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Tarsus Pharmaceuticals by 851.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 590 shares of the company’s stock worth $46,000 after buying an additional 528 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Tarsus Pharmaceuticals by 367.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after buying an additional 558 shares in the last quarter. Finally, Covestor Ltd lifted its stake in shares of Tarsus Pharmaceuticals by 40.0% in the 3rd quarter. Covestor Ltd now owns 1,095 shares of the company’s stock worth $86,000 after acquiring an additional 313 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Recent coverage highlights record Q3 sales and a raised revenue outlook, supporting the view that commercial momentum is improving. The reported $194.57 million in quarterly revenue also exceeded the cited consensus estimate of $187.83 million. Tarsus Pharmaceuticals Could Be 31% Undervalued Following Record Q3 Sales
• Positive Sentiment: Guggenheim raised its price target to $97 from $89 and maintained a Buy rating. HC Wainwright also kept its Buy rating and $106 target, while raising its FY2027–FY2030 earnings forecasts, suggesting greater confidence in longer-term profitability. Tarsus Pharmaceuticals Stock Gets Price Target Increase from HC Wainwright
• Neutral Sentiment: Tarsus plans to participate in upcoming investor conferences. The announcement may provide opportunities for investor updates but does not disclose a new business or clinical development. Tarsus to Participate in Upcoming Investor Conferences
• Negative Sentiment: HC Wainwright cut its Q4 2026 EPS forecast to a loss of $0.55 from a loss of $0.14, and reduced its FY2026 estimate to a loss of $15.85 from $2.25. Separately, Tarsus reported a Q3 loss of $14.40 per share, substantially wider than the cited $1.46 consensus loss. These figures raise concern about near-term costs and profitability despite revenue growth.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.